​

RenovoRx (RNXT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RNXT Stock Rating

RenovoRx stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

RNXT Price Target Upside V Benchmarks

TypeNameUpside
StockRenovoRx-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.36$1.36$1.36
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2522---4
May, 2522---4
Apr, 2522---4
Mar, 2512---3
Feb, 2512---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 17, 2024AscendiantBuyinitialise
Apr 15, 2024Alliance Global PartnersBuyBuyhold
Feb 29, 2024Maxim GroupBuyupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.99$-0.04----
Avg Forecast$-1.01$-0.38$-0.37$-0.12$0.36$1.04
High Forecast$-1.01$-0.38$-0.37$-0.01$0.96$1.04
Low Forecast$-1.01$-0.38$-0.37$-0.23$-0.25$1.04
Surprise %-1.98%-89.47%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$43.00K----
Avg Forecast--$500.00K$13.69M$51.43M$110.60M
High Forecast--$500.00K$13.69M$51.43M$110.60M
Low Forecast--$500.00K$13.69M$51.43M$110.60M
Surprise %------

Net Income Forecast

$-15M $-9M $-3M $3M $9M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-10.23M$-8.81M----
Avg Forecast$-10.34M$-3.94M$-3.84M$-1.23M$3.65M$10.65M
High Forecast$-10.34M$-3.94M$-3.84M$-102.91K$9.88M$10.65M
Low Forecast$-10.34M$-3.94M$-3.84M$-2.37M$-2.57M$10.65M
Surprise %-1.06%123.44%----

RNXT Forecast FAQ

Is RenovoRx stock a buy?

RenovoRx stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that RenovoRx is a favorable investment for most analysts.

What is RenovoRx's price target?

RenovoRx's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.36.

How does RenovoRx stock forecast compare to its benchmarks?

RenovoRx's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for RenovoRx over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is RenovoRx’s EPS forecast?

RenovoRx's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.37, marking a 825.00% increase from the reported $-0.04 in 2024. Estimates for the following years are $-0.12 in 2026, $0.36 in 2027, and $1.04 in 2028.

What is RenovoRx’s revenue forecast?

RenovoRx's average annual revenue forecast for its fiscal year ending in December 2025 is $500K, reflecting a 1062.79% increase from the reported $43K in 2024. The forecast for 2026 is $13.69M, followed by $51.43M for 2027, and $110.6M for 2028.

What is RenovoRx’s net income forecast?

RenovoRx's net income forecast for the fiscal year ending in December 2025 stands at $-3.842M, representing a -56.41% decrease from the reported $-8.814M in 2024. Projections indicate $-1.235M in 2026, $3.65M in 2027, and $10.65M in 2028.